Business Wire

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors

27.4.2026 15:00:00 CEST | Business Wire | Press Release

Share

Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/

Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys)

As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is strengthening its position through the acquisition of a VCSEL company for short-range communications five years ago and the completion of 100G (25G×4) class technology. Furthermore, Seoul Viosys is expanding its business model beyond component supply into a total transceiver solution provider for data interconnects.

Seoul Viosys is currently in discussions with two global leaders in data interconnects (optical communications) on joint technology development, as well as potential joint ventures or OEM manufacturing. The company is also exploring expanded collaboration with additional partners in the United States and Japan. Rather than simply supplying individual components, Seoul Viosys is securing a network of strategic partners to establish its position as a total-solution provider in the data interconnect transceiver market, spanning design, devices, drivers, and modules. Industry observers note that as the optical communications market shifts toward high-speed, low-power, and highly integrated architectures, building a partner ecosystem that connects technology, manufacturing, and applications will be critical, as it is increasingly difficult for any single company to respond alone.

First, Seoul Viosys’ position is underpinned by its patented opto-semiconductor device technologies. Conventional copper interconnects are approaching their physical limits in supporting the ultra-high-capacity, high-speed data transmission required by AI-driven environments. In contrast, Micro LED–based photonic technology enables efficient, high-speed transmission of large volumes of data, making it well-suited for high-density infrastructure such as AI data centers. This low-power, ultra-high-speed communication technology is expected to become essential across future applications, including autonomous vehicle communications and physical AI robotics.

Second, Seoul Viosys’ core competitiveness lies in WICOP, its proprietary technology that eliminates the need for both wires and packaging. This robust structure maximizes light extraction efficiency while enhancing thermal management, enabling high efficiency even at ultra-small scales down to the 1 µm level. Backed by a portfolio of approximately 5,000 opto-semiconductor patents, the company holds a strong advantage in realizing next-generation photonic devices, which well aligns with the market’s shift toward ultra-miniaturization and high integration.

Third, a strong patent barrier is a key competitive advantage. Seoul Viosys, including its subsidiaries, holds approximately 1,800 micro opto-semiconductor patents related to optical communications. Built around these core patents, the company has established a broad and defensible scope of rights, making it extremely difficult for competitors to develop products without infringement. For example, in February, its U.S. subsidiary SETi secured a permanent injunction from a U.S. court against a photonics company with a 40-year history in optoelectronics. Beyond sheer patent volume, the portfolio comprehensively covers core processes, structures, and implementation methods, providing a solid foundation for technological leadership. In addition, its parent company, Seoul Semiconductor, holds an industry-leading portfolio of approximately 15,000 patents in opto-semiconductor packaging and solutions.

Despite years of operating losses, Seoul Viosys has invested tens of millions of dollars annually in Micro LED under its vision of “writing a new history of light,” steadily strengthening its technological competitiveness. The company has collaborated for more than 20 years with a research team at the University of California, Santa Barbara (UCSB), led by Nobel Prize in Physics laureate Shuji Nakamura and Professor Steven DenBaars, and completed development of an ultra-small 1-micrometer (μm)-class device in 2021.

Dr. Dae-Woong Suh, President and Head of R&D at Seoul Viosys, said, “We have built production infrastructure in the United States, Vietnam, and Korea, and are also seeking new partners in India, while strengthening our capabilities in technology collaboration and supply chain response. We are open to working with companies that need our technology, and under strict confidentiality, we will introduce breakthrough products together with our partners.”

According to Grand View Research, the global short-reach optical interconnect market is expected to grow at a compound annual rate of about 20% through 2030, fueled by the expansion of AI infrastructure, to reach approximately $6 billion.

About Seoul Viosys

Seoul Viosys possesses the technological capability to produce full-spectrum opto-semiconductor chips from 200nm to 1,400nm, supported by over 6,000 patents. The company manufactures VCSEL (Vertical Cavity Surface Emitting Laser) and laser diodes, and mass-produces the world’s first “WICOP Pixel,” which integrates R, G, and B for displays into a single chip. Founded in 2002, Seoul Viosys currently holds the world’s No. 1 market share in UV LED. Together with its parent company, Seoul Semiconductor—which holds 15,000 patents—continues to strengthen its technological leadership in the global market. For more information, visit: www.seoulviosys.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260426926495/en/

Contacts

Seoul Viosys
Jinseop Jung
+82-70-4391-8555
jjs8732@seoulsemicon.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye